Additional $12mn to fund further development of Marburg virus vaccine
BARDA has awarded more funding to Public Health Vaccines to support the development of a virally vectored vaccine against Marburg virus infections.
June 25, 2021
by europeanpharmaceuticalreview
Johnson & Johnson to donate 200,000 vaccine regimens to curb Ebola outbreak
To prevent the spread of the Ebola virus in West Africa, Johnson & Johnson is donating vaccines for a WHO early access clinical programme.
May 18, 2021
by europeanpharmaceuticalreview
Gavi to make 500,000 doses of Ebola vaccine available for outbreak response
The global stockpile will provide developing countries responding to Ebola outbreaks with doses of the approved single-dose Ebola vaccine, rVSV∆G-ZEBOV-GP, live, free of charge.
January 25, 2021
by europeanpharmaceuticalreview
FDA approves Ebanga (Ansuvimab-zykl) for the treatment of Ebola
Ebanga was approved based on its ability to reduce 28-day mortality in patients with confirmed Ebolavirus infection.
January 6, 2021
by europeanpharmaceuticalreview
Ridgeback Biotherapeutics’ Ebola treatment scores FDA approval
Ridgeback Biotherapeutics’ Ebanga has been approved by the US Food and Drug Administration (FDA) for the treatment of Ebola in adult and paediatric patients.
December 24, 2020
by pharmatimes
FDA approves Regeneron’s Inmazeb for Ebola infection treatment
The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals’ Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) to treat Ebola virus infection in adult and paediatric patients.
October 16, 2020
by pharmaceutical-technology
Ridgeback Announces Initiation of Expanded Access Protocol for Ebola Treatment
Ridgeback Biotherapeutics announced the implementation of an expanded access protocol to ensure rapid access to its Ebola treatment, ansuvimab, in the Democratic Republic of the Congo (DRC).
August 31, 2020
by americanpharmaceuticalreview
Bavarian Nordic to Manufacture Additional Ebola Vaccines for Janssen
Deal valued at $13.9 million; manufacturing to begin this year.
June 19, 2020
by contractpharma
EMA gives positive opinion to investigational Ebola vaccine regimen
Developed by Janssen, the two-dose regimen has already been given to 60,000 patients and now has the positive opinion of the Committee for Medicinal Products for Human Use (CHMP).
June 9, 2020
by europeanpharmaceuticalreview
New vaccine for Ebola among CHMP recommendations
Johnson and Johnson's experimental two-stage vaccine for protection against Ebola virus disease is among eight medicines backed by the European Medicines Agency's human medicines committee (CHMP) at its May meeting.
June 2, 2020
by pharmatimes
New vaccine for prevention of Ebola virus disease recommended for approval in the EU
The new Ebola vaccine consists of two components, Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo). Zabdeno is given first and Mvabea is administered approximately eight weeks later as a booster.
June 1, 2020
by expresspharma
Merck secures FDA authorisation for Ebola vaccine Ervebo
Merck (MSD) has received the US Food and Drug Administration (FDA) approval for its Ervebo vaccine to prevent Ebola virus disease (EVD) caused by Zaire ebolavirus.
December 23, 2019
by pharmaceutical-technology